SCHEMBL3200374

SCHEMBL3200374

COc1ccc(NC(=O)c2ccc(Cl)c(-c3cncnc3)c2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
KCNH2 Q12809 1/20 0.52
KDM4E B2RXH2 2/20 0.50
MAPT P10636 2/20 0.50
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KCNQ3 O43525 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773257 0.95 MEN1 (0.56) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL3203494 0.89 ABL1 (0.63) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL775074 0.88 NPC1 (0.62) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL775239 0.87 ROCK2 (0.61) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL3218441 0.87 CLK2 (0.57) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL775843 0.86 MEN1 (0.57) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL777653 0.86 MEN1 (0.64) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL776000 0.86 MEN1 (0.70) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL775233 0.86 ROCK2 (0.65) ABL1SMN1; SMN2MEN1KMT2AKEAP1
SCHEMBL775212 0.84 CLK2 (0.59) ABL1SMN1; SMN2MEN1KMT2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B ABL1 1015/4885SMN1; SMN2 3153/4885MEN1 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.